Minutes from the Extraordinary General Meeting in Curasight A/S
June 1, 2021
Curasight A/S, CVR no. 35 24 93 89 (“Curasight” or the “Company”) held an extraordinary general meeting on 1 June 2021 at 11:00 (CET). Due to the COVID-19 situation, the extraordinary general meeting will be held as a completely electronic meeting without physical attendance.
The agenda for the general meeting was as follows:
Election of Dr. Kirsten Drejer as new member of the board of directors
Dr. Kirsten Drejer was elected as new member of the board of directors. A list of Dr. Kirsten Drejer’s management positions in other companies is enclosed as appendix 1.
There were no matters to be presented.
Dr. Kirsten Drejer’s current board directorships and management positions
2000 - KD Invest ApS, CEO
2017 - Bioneer A/S (www.bioneer.dk), Chairman of the board
2017 - Antag Therapeutics ApS (www.antag.com), Chairman of the board
2017 - ResoTher Pharma A/S (www.resotherpharma.com), Chairman of the board
2018 - Zealand Pharma A/S (www.zealandpharma.com), Board member
For more information regarding Curasight A/S, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60